Search
Naporafenib
go.drugbank.com/drugs/DB18865InvestigationalNaporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).
Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-pyridinecarboxamide, n-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-, N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamideTobemstomig
go.drugbank.com/drugs/DB18987InvestigationalTobemstomig is under investigation in clinical trial NCT05908786 (A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular
Pamapimod
go.drugbank.com/drugs/DB19169InvestigationalPamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).
Categories: Heterocyclic Compounds, 1-RingSynonyms: 6-(2,4-Difluorophenoxy)-2-{[3-hydroxy-1-(2-hydroxyethyl)propyl]amino}-8-methylpyrido[2,3-d]pyrimidin-7(8H)-oneTigozertinib
go.drugbank.com/drugs/DB19239InvestigationalTigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC.
Synonyms: 3-ISOQUINOLINAMINE, N-(2-((3S,4R)-3-FLUORO-4-METHOXY-1-PIPERIDINYL)-4-PYRIMIDINYL)-5-(1-METHYLETHYL)-8-((2R,3S)-2-METHYL-3-((METHYLSULFONYL)METHYL)-1-AZETIDINYL)-, N-{2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}-5-(propan-2-yl)-8-[(2R,3S)-2-methyl-3-[(methanesulfonyl)methyl]azetidin-1-yl]isoquinolin-3-amineSabirnetug
go.drugbank.com/drugs/DB19438InvestigationalSabirnetug is under investigation in clinical trial NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)).
Lutetium Lu 177-DTPA-omburtamab
go.drugbank.com/drugs/DB31015InvestigationalLutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]
Bardoxolone
go.drugbank.com/drugs/DB12651InvestigationalBardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. … It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic
Allogeneic Cardiosphere-Derived Cells
go.drugbank.com/drugs/DB15744InvestigationalTNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function. … They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication.
Cergutuzumab amunaleukin
go.drugbank.com/drugs/DB14874InvestigationalCergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid
ONO-8539
go.drugbank.com/drugs/DB15325InvestigationalONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).
Categories: Receptors, Prostaglandin E, EP1 Subtype, antagonists & inhibitors, Heterocyclic Compounds, 1-Ring